Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Practice Guidelines
100%
Executive Summary
100%
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
100%
Obesity
42%
Type 2 Diabetes Mellitus (T2DM)
28%
Cardiometabolic Risk
28%
Hepatocellular Carcinoma
28%
Adaptation
14%
Non-alcoholic Fatty Liver Disease (NAFLD)
14%
Physical Exercise
14%
Fibrosis
14%
Weight Loss
14%
Advanced Fibrosis
14%
Alcohol
14%
Hepatic Steatosis
14%
Bariatric Surgery
14%
Steatosis
14%
Cirrhosis
14%
Decompensated Cirrhosis
14%
Targeted Treatment
14%
Dietary Change
14%
Liver Transplantation
14%
Liver Fibrosis
14%
Tolerability
14%
Metabolic Risk Factors
14%
Preventive Treatment
14%
Preventive Screening
14%
Alcohol Intake
14%
Steatohepatitis
14%
Significant Fibrosis
14%
Portal Hypertension
14%
Nutritional Counseling
14%
Imaging Techniques
14%
Non-cirrhotic
14%
Steatotic Liver Disease
14%
Transient Elastography
14%
Optimal Management
14%
Abnormal Liver Enzymes
14%
Non-invasive Test
14%
Tirzepatide
14%
Resmetirom
14%
Incretin-based Therapy
14%
Acceptable Safety
14%
Targeted Pharmacotherapy
14%
Radiological Signs
14%
Stepwise Approach
14%
Metabolic Dysfunction-associated Steatohepatitis
14%
Semaglutide
14%
Screening Diagnosis
14%
Fibrosis-4 Index
14%
Liver-related Outcomes
14%
Metabolic Compounds
14%
Liver Fibrosis/cirrhosis
14%
Liver Fibrosis Model
14%
Blood-based
14%
Medicine and Dentistry
Metabolic Dysfunction-Associated Steatotic Liver Disease
100%
Fibrosis
57%
Liver Fibrosis
28%
Maturity Onset Diabetes of the Young
28%
Cardiometabolic Risk
28%
Liver Cirrhosis
28%
Hepatocellular Carcinoma
28%
Fatty Liver
14%
Liver Disease
14%
Nonalcoholic Fatty Liver
14%
Alcohol Consumption
14%
Drug Therapy
14%
Steatosis
14%
Decompensated Liver Cirrhosis
14%
Liver Transplantation
14%
Dietary Change
14%
Liver Enzyme
14%
Bariatric Surgery
14%
Steatohepatitis
14%
Portal Hypertension
14%
Targeted Therapy
14%
Nutritional Counseling
14%
Transient Elastography
14%
Case Finding
14%
Semaglutide
14%
Incretin
14%
Imaging Technique
14%
Cancer Transplantation
14%
Tirzepatide
14%
Metabolic Dysfunction-Associated Steatohepatitis
14%